USA Clinical trial diversity not only allows for a better understanding of the safety and efficacy of new therapies in population subgroups but also plays a significant role in reducing health inequities. In conversation with PharmaBoardroom, outgoing president and global chief executive of the Drug Information Association (DIA) Barbara Lopez Kunz,…
InFocus BACK TO HOME Patient Engagement in the Era of CAR-T BACK TO HOME Patient Engagement Roundtable: A Varied Global Picture As complex cutting-edge therapies come online, industry sponsors are increasingly looking to engage with patients, caregivers, and advocacy groups earlier and more broadly in the drug development…
InFocus BACK TO HOME Patient Engagement in the Era of CAR-T BACK TO HOME CGT, Real World Evidence & The Patient Experience One of the enduring conundrums around ground-breaking and potentially paradigm-shifting treatments such as CAR-T is the ever-thorny question of how fast to move them to market…
InFocus BACK TO HOME Patient Engagement in the Era of CAR-T BACK TO HOME CAR-T and the Art of Managing Expectations Chimeric antigen receptor (CAR-T) therapy was first approved by the US FDA back in 2017 amid a great deal of fanfare and high expectations among patients about…
InFocus BACK TO HOME Patient Engagement in the Era of CAR-T BACK TO HOME Rendering CGT Genuinely Patient Centric In recent years, the much-discussed concept of “patient centricity” has been top-of-mind across all corners of the pharma industry. This is especially pertinent now that many innovative drug makers…
InFocus BACK TO HOME Patient Engagement in the Era of CAR-T BACK TO HOME Marc Boutin Global Head of Patient Engagement, novartis SHARE Share on twitter Share on linkedin “How are you today?” For patients, this question may be a challenge. Honest answers can stop a conversation straight away. I know…
InFocus HOMEPAGE Patient Engagement in the Era of CAR-T In recent years, the much-discussed concept of “patient centricity” has been top-of-mind across all corners of the pharma industry. This is especially pertinent now that many innovative drug makers are seeking to become much more than just purveyors of pills and expand…
InFocus BACK TO HOME Cell & Gene Therapy BACK TO HOME Stefan Hendriks Global Head, Cell & Gene, Novartis Oncology Stefan Hendriks, Global Head of Novartis Oncology’s Cell & Gene division outlines the company’s progression to becoming the global leader in cell and gene therapies, the strategy he…
Cell & Gene Therapy Two years on from the introduction of Novartis Oncology’s CAR-T therapy to Europe, Emnuele Ostuni, the firm’s European head of cell and gene therapy, spoke to PharmaBoardroom about the pioneering product’s journey to market, what has been learnt along the way, and how his team has worked to assuage concerns…
Cell & Gene Therapy Emanuele Ostuni, Novartis Oncology’s head of cell and gene therapy for Europe, gives an overview of the introduction of the company’s CAR-T therapy to Europe, the work still to be done to get this product to more patients who need it across the continent, and the future of cell and…
Cell & Gene Therapy Deloitte’s Omkar Kawalekar, Hussain Mooraj, and Amit Agarwal examine the evolution and future of cell and gene therapy manufacturing and the areas in which biopharma firms need to invest in order to succeed in this emergent field. Cell and gene therapies (CGT) are the next evolution of personalized health…
Artificial Intelligence Digital health deal values in biopharma jumped to USD 6.4 billion in 2019, largely thanks to software company Dassault Systemes Americas Corp.’s USD 5.9 billion acquisition of health tech company Medidata Solutions, according to analysis by S&P Global Market Intelligence. “Traditional investors in the digital health startup space have generally…
See our Cookie Privacy Policy Here